Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders
Authors:
Open Access
- 16 September 2024
- journal article
- review article
- Published by Elsevier in Biological Psychiatry
- Vol. 97 (6) , 563-579
Abstract
No abstract availableKeywords
Funding Information
- H2020 Marie Skłodowska-Curie Actions (101031962)
- H2020 Marie Skłodowska-Curie Actions (01031317)
- Infectious Diseases Society of America Foundation
- Brain and Behavior Research Foundation (26826)
This publication has 144 references indexed in Scilit:
- Comparative Effectiveness of Different Treatment Pathways for Opioid Use DisorderJAMA Network Open, 2020
- Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use DisorderJAMA Psychiatry, 2019
- Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United StatesJAMA Network Open, 2019
- The Burden of Opioid-Related Mortality in the United StatesJAMA Network Open, 2018
- NMDA Receptor Blockade in the Prelimbic Cortex Activates the Mesolimbic System and Dopamine-Dependent Opiate Reward SignalingPsychopharmacology, 2014
- Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsPsychopharmacology, 2010
- Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval taskPsychopharmacology, 2005
- NMDA Receptor in Nucleus Accumbens is Implicated in Morphine Withdrawal in RatsNeurochemical Research, 2004
- The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humansPsychopharmacology, 2001
- Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neuronsJournal of Comparative Neurology, 1999